New drug for advanced stomach cancer that has stopped responding
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced stomach cancer or cancer at the junction of the stomach and esophagus.
- You have already tried at least two prior treatments, and they did not work well enough.
- Your tumor tests positive for a specific protein called CLDN18.2 (checked on a biopsy).
- You are generally able to care for yourself and are not bedridden (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
This trial tests a new drug, ATG-022, compared with standard treatments for people with advanced stomach or gastroesophageal junction cancer that has grown after at least two previous treatments. The tumor must have a specific marker called Claudin 18.2.
Hear when a new Gastric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.